A novel SPECT/CT imaging technique has been developed to effectively differentiate between inflammation and fibrosis in patients with interstitial lung disease (ILD). Presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting, this method utilizes the imaging agent 99mTc-maraciclatide, which highlights new blood vessel formation, a hallmark of inflammation. The study involved 15 participants, including patients with idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis, alongside healthy controls. Results showed that ILD patients exhibited distinct tracer uptake patterns, which could inform treatment decisions regarding anti-inflammatory therapies. Given the critical nature of distinguishing between fibrotic scarring and inflammation, this imaging advancement could significantly enhance patient management. The FDA has granted Fast Track designation to 99mTc-maraciclatide for ILD imaging, with expectations for it to be available within two years following a Phase 3 study.